Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo- controlled, double-blind, pilot study

Psychoneuroendocrinology

Volumn 24, Issue 6, 1999, Pages 657-678

  Asthana, Sanjay ^a,b   Craft, Suzanne ^a,b   Baker, Laura D ^a,b   Raskind, Murray A ^a,b   Birnbaum, Roger S ^a,b   Lofgreen, Cassin P ^a   Veith, Richard C ^a,b   Plymate, Stephen R ^a,b  

^a Educ Clin Ctr (GRECC)   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Cognition; Dementia; Estrogen; Memory; Neuroendocrine

Indexed keywords

ESTRADIOL;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; NEUROPSYCHOLOGICAL TEST; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033003028     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(99)00020-7     Document Type: Article

References (54)

1. Aglio E., Valenti G., Hoffman A., Zuccarelli A., Passeri M., Ceda G. Lack of effect of transdermal estrogen on the growth hormone-insulin-like growth factor axis. Horm. Metab. Res. 26:1994;211-212.
2. Baldereschi M., Di-Carlo A., Lepore V. et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 50(4):1998;996-1002.
3. Benton A., Hamsher K.D., Varney N., Spreen O. Contributions to Neuropsychological Assessment. 1983;Oxford University Press, New York.
4. Birge S. Estrogen and the treatment of Alzheimer's disease. Am. J. Med. 103(3A):1997;36S-45.
5. Birge S. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia. J. Am. Geriatr. Soc. 44:1996;865-870.
6. Blessed G., Tomlinson B.E., Roth M. The association between measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br. J. Psychiatry. 114:1968;797-822.
7. Buschke H. Selective reminding for analysis of memory and learning. J. Verb. Learn. Verb. Behav. 12:1973;543-550.
8. Chetkowski R., Meldrum D., Steingold K. et al. Biological effects of transdermal estradiol. N. Engl. J. Med. 314:1986;1615-1620.
9. Cummings J., Coffey C. Neurobiological basis of behavior. Coffey C., Cummings J. Textbook of Geriatric Neuropsychiatry. 1994;72-96 American Psychiatric Press, Inc, Washington, DC.
10. Cummings J., Cyrus P., Bieber F., Mas J., Orazem J., Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 50:1998;1214-1221.
11. Davidson M., Stern R. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr. Clin. North. Am. 14:1991;461-482.
12. Dawson-Hughes B., Stern D., Goldman J., Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement therapy. J. Clin. Endocrinol. Metab. 63:1986;424-432.
13. Dodrill C. A neuropsychological battery for epilepsy. Epilepsia. 19:1978;611-623.
14. Duenas M., Torres-Aleman I., Naftolin F., Garcia-Segura L. Interaction of insulin-like growth factor-I and estradiol signalling pathways on hypothalamic neuronal differentiation. Neuroscience. 74(2):1996;531-539.
15. Evans M., Halter J., Porte D.J. Comparison of double-and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma. Clin. Chem. 24:1978;567-570.
16. Fillit H., Weiner H., Cholst I. et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
17. Folstein M.F., Folstein S.E., Mc Hugh P.R. Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
18. Goebelsmann U., Bernstein G., Gale J. et al. Serum gonadotropin, testosterone, estradiol, and estrone levels prior to and following bilateral vasectomy. Lepow J., Crozier R.E. Vasectomy: Immunologic and Pathophysiologic Effects in Animals and Man. 1979;165-175 Academic Press, New York.
19. Hachinski V.C., Iliff L.D., Zilhka E. et al. Cerebral blood flow in dementia. Arch. Neurol. 32:1975;632-637.
20. Henderson V., Paganini-Hill A., Emanuel C., Dunn M., Buckwalter J. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch. Neurol. 51:1994;896-900.
21. Henderson V., Watt L., Buckwalter J. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology. 21:1996;421-430.
22. Hong M., Lee V. Insulin and insulin-like growth factor-I regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272(31):1997;19547-19553.
23. Honjo H., Ogino Y., Naitoh K. et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J. Steroid. Biochem. 34:1989;521-525.
24. Honjo H., Ogino Y., Tanaka K. et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled, double-blind study. J. Jpn. Menopause. Soc. 1:1993;167-171.
25. Kawas C., Resnick S., Morrison A. et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology. 48:1997;1517-1521.
26. Kelly J., Rajkovic I., O'Sullivan A., Sernia C., Ho K. Effects of different oral estrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women. Clin. Endocrinol. 39:1993;561-567.
27. Knapp M., Knopman D., Solomon P., Pendlebury W., Davis C., Gracon S. A 30- week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J. Am. Med. Assoc. 271:1994;985-991.
28. Levrant S., Barnes R. Pharmacology of estrogens. Lobo R. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. 1994;57-68 Raven Press, Ltd, New York.
29. Masters B., Shemer J., LeRoith D., Raizada M. Insulin-like factor receptors in the central nervous system: phosphorylation events and cellular mediators of biological function. LeRoith D., Raizada M. Molecular and cellular biology of IGFs and their receptors. 1989;341-358 Plenum Press, New York.
30. McEwen B., Alves S., Bulloch K., Weiland N. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 48(Suppl. 7):1997;S8-S15.
31. McEwen B., Bigeon A., Fischetee C., Luine V., Parsons B., Rainbow T. Toward a neurochemical basis of steroid hormone action. Martin L., Ganong W. Frontiers in Neuroendocrinology. 8:1984;153-176 Raven Press, New York.
32. McEwen B., Woolley C. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp. Gerontol. 29:1994;431-436.
33. McKhann G., Drachman D., Folstein M., Katzman R., Price D.L., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
34. McNeil M., Prescott T. Revised Token Test. 1978;University Park Press, Baltimore.
35. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. J. 41:1994;361-371.
36. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause. 1:1994;125-130.
37. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia. 6:1995;99-107.
38. Overall J., Gorham D. Introduction-the brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharm. Bull. 24:1988;97-99.
39. Paganini-Hill A., Henderson V. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:1994;256-261.
40. Phillips S., Sherwin B. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 17:1992;485-495.
41. Phillips S., Sherwin B. Variations in memory function and sex steroid hormones across the menstrual cycle. Psychoneuroendocrinology. 17:1992;497-506.
42. Plymate S., Birnbaum R., Rosen C. et al. Proteolysis of insulin-like growth factor binding protein-3 in the male reproductive tract. J. Clin. Endocrinol. Metabol. 81:1996;618-624.
43. Plymate S., Hobbs C., Rosen C., Adler R. Testosterone administration increases insulin-like growth factor-I levels in normal men. J. Clin. Endocrinol. Metab. 77:1993;776-779.
44. Riedel W., Jolles J. Cognition enhancers in age-related cognitive decline. Drugs Aging. 8(4):1996;245-274.
45. Rogers S., Friedhoff L. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
46. Rollero A., Murialdo G., Fonzi S. et al. Relationship between cognitive function, growth hormone, and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology. 38:1998;73-79.
47. Sara V., Hall K., Von Holz H., Humbel R., Sjogren B., Wetterberg L. Evidence for the presence of specific receptors for insulin-like growth factors I (IGF-I) and 2 (IgF-2) and insulin throughout the adult human brain. Neurosci. Lett. 34:1982;39-44.
48. Sherwin B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 13:1988;345-357.
49. Slowinska-Srzednicka J., Zgliczynski S., Jeske W. et al. Transdermal 17 β-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J. Endocrinol. Invest. 15:1992;533-538.
50. Stroop J. Studies of interference in serial verbal reactions. J. Exp. Psychology. 18:1935;643-662.
51. Tang M., Jacobs D., Stern Y. et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
52. Troy S., Hicks D., Parker V., Jusko W., Rofsky H., Porter R. Differences in pharmacokinetics and comparative bioavailability between premarin and estratab in healthy postmenopausal women. Curr. Ther. Res. 55:1994;359-372.
53. Wechsler D. A standardized memory scale for clinical use. J. Psychol. 19:1945;87-95.
54. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Med. Assoc. 279:1998;688-695.